Ansell (ASX:ANN): FY26 Results, Manufacturing Expansion and Safety Products

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Ansell (ASX:ANN): FY26 Results, Manufacturing Expansion and Safety Products

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell (ASX:ANN) reported approximately USD 2.1bn in FY26 revenue.
FY26 first-half Healthcare EBIT increased 12.6% to USD 72.5mn.
The company inaugurated a surgical glove manufacturing facility in India in September 2026.
Industrial and Healthcare safety products remain its two principal business segments.

Ansell Limited designs and manufactures protective gloves, clothing and related safety products for healthcare and industrial workplaces across international markets. The company’s FY26 reporting and manufacturing investments provide the latest context for its operations. Shares in Ansell (ASX:ANN) closed at AUD 46.52 after the market session ended on 26 October 2026, a rise of 0.54% for the day. Its recent disclosures address sales performance, production capacity, product development and continuing cost-management initiatives.

Company Business

Ansell (ASX:ANN) operates through Healthcare and Industrial businesses, supplying protection products to hospitals, surgical centres, laboratories, life-science manufacturers and a range of industrial workplaces. Its Healthcare portfolio includes surgical, examination and single-use gloves, together with cleanroom products. The Industrial business provides hand and body protection for mechanical, chemical and other occupational hazards.

Products are marketed across more than 100 countries. Manufacturing, product formulation, certification and distribution arrangements are therefore central to operations. Demand differs by customer setting: healthcare purchasing follows clinical and infection-control requirements, while industrial orders reflect workplace activity, safety specifications and replacement cycles. The company also invests in product design and material technology to address protection and usability requirements.

Recent Development

In September 2026, Ansell (ASX:ANN) inaugurated a manufacturing facility in Kovai, India, focused on surgical gloves. The company stated that production had begun for the local market and that further capacity would be introduced to serve strategic markets, including the United States and selected European countries. The facility expands Ansell’s manufacturing footprint and adds another site to its surgical supply network.

Ansell also announced the opening of an AXIS experience and innovation studio near Coimbra, Portugal, in late September 2026. The site forms part of its customer-focused work in safety product development and testing. These announcements followed the company’s FY26 full-year results released in August and reflect separate manufacturing and commercial initiatives rather than an explanation of daily share trading.

Its 2026 operating program includes manufacturing and sourcing productivity, implementation of commercial systems and integration of acquired product ranges. The company’s established portfolio spans Healthcare and Industrial markets, with shifts in sales mix affecting production utilisation and operating margins.

Financial Performance and Sector Context

Ansell (ASX:ANN) reported FY26 annual revenue of approximately USD 2.1bn. In the first half of FY26, Healthcare segment sales were USD 558.7mn, compared with USD 562.3mn in the prior corresponding period, a decline of 0.6%. Healthcare EBIT nevertheless increased 12.6% to USD 72.5mn from USD 64.4mn, with the segment EBIT margin rising to 13.0% from 11.5%.

The company attributed first-half margin progress to synergies from its acquired businesses, lower freight expenditure and sourcing productivity. Within Healthcare, surgical and cleanroom demand provided areas of growth, while examination and single-use products faced softer volumes in certain categories. Industrial performance depends on demand for hand, arm and chemical protection across manufacturing, construction and specialist industries.

Healthcare procurement, infection-control standards, raw-material prices, transport costs and tariff rules influence the trading environment. The manufacturing network also creates exposure to foreign-currency movements and regional supply conditions. Full-year reporting and subsequent disclosures will establish how these variables affect revenue mix, profitability and operating cash generation.

Risks to Consider

Ansell (ASX:ANN) faces changes in end-market demand, raw-material and freight costs, trade tariffs and foreign-exchange rates. Expansion of manufacturing capacity can involve commissioning, quality-control and production-efficiency challenges. Product certification, labour practices and supplier compliance are continuing operational considerations. The pace of enterprise-system upgrades and anticipated integration efficiencies can also affect expenses and execution schedules.

What to Watch Next

For Ansell (ASX:ANN), developments to monitor include additional production capacity at the India facility, updates on product mix across Healthcare and Industrial operations, and FY27 earnings disclosures. The company has scheduled its 2026 annual general meeting for November. Further reporting will show how commercial system investments, manufacturing productivity and regional sales trends flow through to cash generation and margins.

Key Insights

Ansell’s FY26 revenue base, improvement in first-half Healthcare profitability and expansion of surgical manufacturing capacity provide measurable business developments. Its exposure to healthcare and industrial workplaces gives it multiple customer markets, while input costs, tariffs, currency movements and operational execution remain relevant considerations. Future financial reporting and manufacturing updates will clarify the progress of these initiatives.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.